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Abstract
Background: A recent study reported that an 18-analyte
multiplexed plasma panel of signaling proteins differentiated
Alzheimer’s disease (AD) from controls. This study meas-
ured mRNA expression for nine of these promising bio-
markers in 23 AD patients and 23 age- and sex-matched
controls.
Methods: Total RNA was isolated from PaxGene RNA tubes.
Relative mRNA expression levels of CCL5 wRANTESx,
CSF1, ICAM1, IGFBP6, IL1A, IL3, IL8, PDGFB and TNF
were determined by Q-RT-PCR, with GAPDH as house-
keeping gene.
Results: A panel of five markers (CCL5, CSF1, ICAM1,
IL8, TNF) with detectable expression levels in all individuals
differed between AD patients and controls (p interaction
-0.10). Especially, the relative expression level of CCL5
was lower in AD patients than in controls (p-0.005). Across
groups, levels of both CCL5 and TNF were correlated to
CSF levels of t (rs0.39, rs0.32), pt-181 (rs0.38,
rs0.33), and MMSE (rs–0.31, rs–0.33, all p-0.05).
Conclusions: The measured panel, and especially CCL5,
could aid in the differentiation of AD from controls.
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Introduction
Alzheimer’s disease (AD) is the most prevalent form of
dementia and is characterized by progressive cognitive
impairment that gradually robs a patient of his or her inde-
pendence. During life a diagnosis of AD is based on clinical
criteria (1), but these rely on advanced symptomatology.
To develop new treatment strategies, and for individually
tailored management of patients, an earlier diagnosis is war-
ranted. AD-related brain pathology and subsequent neuro-
degeneration precede clinical symptoms. Biological markers
of this pathology could be of help to identify the onset of
disease in vivo. In tertiary referral settings, cerebrospinal flu-
id (CSF) biomarkers amyloid b 1–42 (Ab42), total tau (t)
and tau phosphorylated at threonine 181 (pt-181) have been
shown to perform well for differentiation of AD from healthy
controls with sensitivity and specificity of 80%–90% (2).
However, assessment of these markers is troubled by lack of
standardized procedures (3) and obtaining CSF by lumbar
puncture is considered by many to be invasive. Efforts have
been made to develop a plasma test for AD to overcome
these problems, with limited success (4, 5).
A recent study reported that an 18-analyte multiplexed
plasma panel could differentiate AD from controls, using
plasma signaling proteins (6). In that study, the abundance
of 120 known signaling proteins were measured by filter-
based, arrayed sandwich ELISAs. A set of 18 signaling pro-
teins in blood plasma was found to classify blinded samples
from AD and controls with close to 90% accuracy. These
proteins were involved in pathways of immune response,
hematopoiesis, apoptosis and neuronal support. Of these sig-
nature proteins, tentatively called the ‘‘cellular communi-
come’’, nine have been reported to be specifically related to
AD. Until now these results have not been independently
replicated. Additionally, the study is hampered by method-
ological issues, e.g., there were age differences between the
groups examined.
In the current study, we performed messenger RNA
(mRNA) expression analyses using a quantitative RT-PCR
technique for the nine AD related signaling proteins in
23 AD patients and 23 age- and sex-matched controls. We
used Q-RT-PCR because of the assay performance and the
ease to set up a quantitative molecular multimarker analysis
of RNA, compared to the filter-based, arrayed sandwich
ELISA analysis of proteins. The first aim of the current study
was to validate the value of these nine blood markers in the
discrimination of AD patients from controls. The second aim
was to obtain insight in the biological pathways associated
with AD, by analyzing correlations of mRNA expression for
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the signaling proteins with age, mini-mental state examina-
tion (MMSE) and levels of CSF biomarkers Ab42, t and
pt-181.
Materials and methods
Study population
We included 23 patients with a diagnosis of probable AD and 23
patients with subjective complaints, who served as controls, from
our memory clinic. Groups were matched for age and sex: AD
patients were 64"7 years old and 44% were female, controls were
64"7 years old and 48% were female. All patients underwent a
standard dementia screening including physical and neurological
examination as well as laboratory tests, EEG and brain magnetic
resonance imaging (MRI). Cognitive screening included the MMSE,
but usually involved comprehensive neuropsychological testing. The
diagnosis of probable AD was made according to the criteria of the
National Institute of Neurological and Communicative Disorders
and Stroke and the Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA) in a consensus meeting (1). When
the results of all examinations were normal, patients were consi-
dered to have subjective complaints wi.e., did not fulfill criteria for
mild cognitive impairment (7)x. For most patients (ns41) CSF
biomarker levels of Ab42, t and pt-181 were determined (8). If
possible patients were additionally selected based on CSF biomarker
levels, with abnormal levels for the included AD patients and nor-
mal levels of the patients with subjective memory complaints, to
obtain a more certain diagnosis. Levels of CSF Ab42-550 pg/mL,
CSF t)375 pg/mL and CSF pt-181)52 pg/mL were considered
abnormal (9). The Ethical Review Board of the VU University
medical center approved the study, all subjects gave written
informed consent and the study was performed within the confines
of the Helsinki Declaration.
RNA isolation
Peripheral blood was collected in PAXgene tubes (PreAnalytiX) and
left at room temperature for at least 2 h before freezing at –208C,
as was indicated by the manufacturer. Automated RNA isolation
was performed on the Biorobot MDX (Qiagen, Benelux b.v., Venlo,
The Netherlands) according to the manufacturer’s instructions
(PAXgene Blood RNA Mdx kit). Yields and purity of isolated RNA
were determined by spectrometric analysis (Nanodrop). Samples
were stored at –808C.
Quantitative RT-PCR
The relative expression levels of nine target genes were determined
using TaqMan gene expression assays (Applied Biosystems) and
detected on an ABI7300/SDS platform (Applied Biosystems, Inc.).
Selected target genes were insuline-like growth factor-binding pro-
tein 6 (IGBP6), interleukin-8 (IL8), inter-cellular adhesion molecule 1
(ICAM1), chemokine (C-C motif) ligand 5 (CCL5 – also known as
RANTES), colony-stimulating factor 1 (CSF1), tumor necrosis fac-
tor a (TNF), interleukin-3 (IL3), interleukin-1 a (IL1A) and plate-
let-derived growth factor subunit B (PDGFB). As a calibrator
(housekeeping gene), glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) was used. The 10 genes correspond with the TaqMan
assay catalog numbers GAPDH (Hs00266705_g1), IGBP6
(Hs00181853_m1), IL8 (Hs99999034_m1), ICAM-1 (Hs99999152_
m1), CCL5 (Hs00174575_m1), CSF1 (hs00174164_m1), TNFa
(hs99999043_m1), IL3 (hs00174117_m1), IL1a (hs99999028_m1),
PDGFB (hs00234042_m1). The RT-PCRs were set up according to
the manufacturer’s instructions (GeneAmp EZ rTth RNA PCR re-
agent set, Applied Biosystems, Inc.). RT-PCR reactions were per-
formed in 20 mL with 1=Taqman EZ Buffer, 3 mM manganese
acetate, 300 mM dATP, 300 mM dCTP, 300 mM dGTP, 600 mM
dUTP, 1 mL TaqMan gene assay mix (20=), 0.1 U/mL rTth DNA
Polymerase, 0.01 U/mL AmpErase UNG, 100 ng total RNA. After
2 min at 508C, 30 min at 608C and 5 min at 958C, 40 PCR cycles
were performed as follows: 948C for 20 s (denaturation), 608C for
1 min (annealing and elongation). Each TaqMan RT-PCR assay was
performed in triplicate in 96-well plates and ROX as a passive ref-
erence. Each plate had a reference RNA (100 ng) and a negative
control, milliQ water. mRNA expression was given as cycle thresh-
old (CT), where a higher CT indicates lower mRNA expression. All
flag settings were used and wells with CT -36, bad ROX passive
reference, standard deviation )0.5, no amplification, relative noise
)4, were omitted. The delta CT (DCT) was calculated with the
StatMiner software (Integromics, Inc.), using GAPDH as endoge-
nous control.
Data analyses
For statistical analysis, SPSS version 15.0 (for Windows) was used.
Results are expressed as means (SD) unless indicated otherwise.
Frequency distributions for categorical variables were compared
with x2-tests and Student t-tests were used to compare continuous
variables. MANOVA for repeated measures was used with mRNA
expression levels (DCT) of the individual genes as within-subjects
variable and diagnosis as between-subjects variable. Subsequently,
mRNA expression (DCT) was compared between groups for the
individual mRNA genes using Student t-tests. For the purpose of
graphical representation, relative expression (RQ) was calculated
with the formula 2–DDCT, with DDCT as the mean difference of DCT
between AD patients and controls. In this approach, the mean value
of the control group was arbitrarily set to 1. Pearson correlations
were used to determine correlations among the different mRNA
genes (using DCT), and between each mRNA gene and MMSE, age
and levels of CSF biomarkers Ab42, t and pt-181. Correlations
were determined first for the whole group, and then after stratifi-
cation for diagnosis. In general, statistical significance was set at
p-0.05. Interactions were considered significant if p-values were
lower than 0.10.
Results
Table 1 represents patient characteristics according to diag-
nosis. AD patients had a lower score on the MMSE, lower
levels of CSF Ab42 and higher levels of t and pt-181 than
controls (all p-0.001).
The expression of mRNAs of IGFB6, PDGFB, IL1A and
IL3 was detectable in less than half of the patients, which
made analyses unreliable. ANOVA for repeated measures
revealed that mRNA expression levels of ICAM1, IL8,
CCL5, CSF1 and TNF were in general, albeit non-signifi-
cantly, lower in AD patients than in controls (ps0.07). In
addition, there was an interaction for diagnosis*mRNA
genes (p-0.10), indicating that the pattern of expression of
mRNA genes differed by group (Figure 1). Post-hoc analyses
of individual mRNA genes showed that expression of mRNA
CCL5 was lower in AD patients than in controls (p-0.005),
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Table 1 Baseline characteristics.
Control Alzheimer’s disease
(ns23) (ns23)
Female, n (%) 10 (44%) 11 (48%)
Age, years 64"7 64"7
MMSE 28"1 20"4b
CSF Ab42, pg/mLa 829"278 463"99b
CSF t, pg/mLa 292"155 646"329b
CSF pt-181, pg/mLa 56"21 98"49b
ICAM1, DCT 3.5"2.3 4.5"3.2
IL8, DCT 6.7"1.0 6.5"1.2
CCL5, DCT –0.4"0.6 0.1"0.5
CSF1, DCT 4.7"0.6 4.8"0.7
TNF, DCT 4.6"0.8 4.9"0.8
Data are provided as mean"SD, unless indicated otherwise. Con-
trols were patients with subjective memory complaints. aData avail-
able for 20 controls and 21 AD patients. bp-0.001. Ab42,
amyloid-b 42; t, total tau; Pt-181, tau phosphorylated at threonine
181; ICAM1, inter-cellular adhesion molecule 1; IL8, interleukin-8;
CCL5, chemokine (C-C motif) ligand 5; CSF1, colony-stimulating
factor 1; TNF, tumor necrosis factor a; DCT, mRNA expression;
AD, Alzheimer’s disease; MMSE, mini mental state examination.
Figure 1 Boxplots of relative expression of blood mRNA biomarker in Alzheimer’s disease and controls.
Please note that statistical analysis was performed using DCT, whilst for graphical representation, relative expression (RQ) was used. RQ
was defined as expression in AD patients compared to controls, and was calculated with the formula 2–DDCT, with DDCT as the mean
difference of DCT between AD patients and controls. In this approach, the mean value of the control group was arbitrarily set to 1. The
boxplot figures indicate the minimum, first quartile, median, third quartile and maximum values of the RQ. The light gray bars represent
the controls and the dark gray bars the AD patients. *p-0.005.
while there were no other significant differences between
groups.
Across groups, there were correlations between CCL5 and
TNF (rs0.42, p-0.005) and between TNF and IL8
(rs0.35, p-0.05). In addition, there were correlations for
CCL5 with CSF t levels (rs0.39, p-0.05), CSF pt-181
levels (rs0.38, p-0.005) and with MMSE (rs–0.31,
p-0.05), indicating that lower CCL5 mRNA expression
(higher DCT) was associated with higher t and pt-181 levels
and lower MMSE. Also for TNF there were correlations with
CSF t levels (rs0.32, p-0.05), CSF pt-181 levels
(rs0.33, p-0.05) and with MMSE (rs–0.33, p-0.05).
After stratification for diagnosis, correlations between
CCL5 and TNF remained significant for controls (rs0.46,
p-0.05). In addition, there were also correlations between
IL8 and CCL5 (rs–0.42, p-0.05) and IL8 and Ab42 levels
(rs–0.51, p-0.05). In the group of AD patients there was
a correlation for IL8 with TNF (rs–0.45, p-0.05), while
correlations with age, MMSE or CSF biomarker levels
disappeared.
Discussion
We have shown that a panel of five mRNA genes differed
between AD patients and controls of similar age and sex.
Further investigation showed that this effect was mostly
attributable to mRNA expression of CCL5, which was lower
in AD patients compared to cognitively healthy subjects. The
results of this study, using Q-RT-PCR to measure mRNA
expression in blood samples, were different than the report
of an 18-analyte multiplexed plasma protein panel that
reportedly differentiated AD from controls with high accu-
racy (6).
We used a novel approach to validate a previously
published panel of signaling proteins for the differentiation
of AD patients from controls. With this method we were able
to set up a quantitatively molecular multimarker analysis by
measuring signaling activity at mRNA level. In our study,
nine of the 18 earlier reported markers were measured, since
these nine seemed most related to AD (6). Our results did
not provide affirmative evidence for the results of this pre-
viously reported panel which showed 90% diagnostic accu-
racy for the differentiation of AD from controls (6). Two
other groups also attempted to replicate the results of the
18-analyte multiplexed plasma panel, and obtained negative
results as well, as is shown in Table 2 (10, 11). One study
showed no differences of protein levels between groups and
poor diagnostic accuracy of the panel (11). The second rep-
lication study showed higher levels of CCL5 in AD as com-
pared to controls, also with low diagnostic accuracy (10). It
is disappointing that the excellent discriminative value of the
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Table 2 Comparison of results of studies evaluating signaling activity in blood samples for the differentiation of Alzheimer patients and
control subjects.
Ray et al. (6) (protein) Marksteiner et al. (10) (protein) Soares et al. (11) (protein) Present study (mRNA)
CCL5 x ≠ NS x
CSF1 x NS – NS
ICAM1 ≠ NS NS NS
IL8 ≠ NS NS NS
TNF x NS NS NS
IGFBP6 ≠ – – –
IL1A x NS – –
IL3 x NS NS –
PDGFB x NS – –
≠ and x, levels of protein or mRNA expression were significantly increased, respectively decreased in AD compared to controls; NS,
levels of protein or mRNA expression were not significantly different between AD and controls; –, no data available.
reported 18-analyte multiplexed plasma panel has not been
validated by either of the two replication studies or by our
study. It appears that the results of the initial study reporting
the 18-analyte multiplexed plasma panel should be consid-
ered with reservations. We used a different approach than the
previous two replication studies, by measuring mRNA
instead of protein levels. Possibly, the measurement of
mRNA levels, instead of protein levels, could lead to a dif-
ferent result. This could for instance be caused by a differ-
ence in turn-over between mRNA and protein; the
breakdown of protein could be higher than of mRNA. In
addition, proteins in blood can be derived from several
organs, like the liver or fat cells, while in this study mRNA
was measured in blood cells only. Further studies could
examine both protein and mRNA levels together, to get fur-
ther insight in these possible differences. In our study, unfor-
tunately expression levels of four mRNA genes (IGFB6,
PDGFB, IL1A and IL3) were not available for analyses. The
concentration of mRNA of these genes was probably too low
for the protocol we used. Although this can be seen as a
limitation, it is most likely not a consequence of the used
assay or study design, but of the markers themselves: the
high level of inter-individual biological variation prevents
their reliable detection in all individuals in general and there-
by prohibits its use as a reliable marker for AD.
We did not succeed in replicating the promising results of
the earlier study with one exception. In our study we found
lower CCL5 expression in AD, which was congruent with
the initial study (6), but not with both other studies (10, 11).
The CCL5 gene is one of several C-C motif cytokine genes
clustered on the q-arm of chromosome 17. Cytokines are a
family of secreted proteins involved in immunoregulatory
and inflammatory processes. The CC-cytokines are proteins
characterized by two adjacent cysteines. The cytokine enco-
ded by this gene functions as a chemo-attractant for blood
monocytes, memory T-helper cells and eosinophils. It has
been found that CCL5 levels are up-regulated in microglia
and cerebrovascular tissue in the first phase after exposure
to amyloid (12, 13), while after a longer period of exposure
a decrease of CCL5 was shown (14). Furthermore, CCL5
has been associated with the prevention of amyloid associ-
ated cell death (15). It could be hypothesized that in an early
phase of exposition to amyloid, microglia cells respond by
producing CCL5 to inhibit apoptosis, while in later stages
this system fails and patients suffer from an insufficient pro-
duction of CCL5, which leads to the pathologic process of
AD. CCL5 levels have been found to be increased by about
65% in cognitively healthy centenarians (mean age 101),
compared to subjects at young (mean age 28) and at older
ages (mean age 71) (16). This up-regulation of CCL5 expres-
sion might be necessary to prevent immuno-pathological
damage, allowing subjects to reach the age of 100 years
cognitively healthy. Further longitudinal studies in healthy
aging and the early phase of AD (mild cognitive impairment)
should be performed to clarify this. Next to lower CCL5, we
also found lower TNF mRNA expression in patients with
higher t and pt-181 levels and lower MMSE, e.g., in
patients with a typical AD profile. Lower levels of TNF were
also seen in the initial study (6). Lower expression of TNF
in AD has also been shown before by several other studies
(17–19) and TNF was shown to be decreased in brain areas
of AD patients (20). It seems possible that mRNA expression
of the signaling proteins CCL5 and TNF are indeed related
to AD pathology. Further support for the notion that meas-
uring mRNA is a promising direction to seek for new AD
biomarkers is provided by the observed associations between
CCL5 and TNF levels and CSF biomarkers for AD patho-
logy. It is tempting to speculate that mRNA expression of
signaling proteins in blood was indeed related to AD-asso-
ciated brain changes. In addition, RNA expression profiling
permits rapid screening of markers by assays that have an
easy set up, compared to ELISA or proteomics studies, while
the only requirement is information on the target sequence.
We have now examined a small seemingly promising group
of signaling mRNA markers, but probably many more sig-
naling processes are involved in the pathogenesis of AD, and
further exploration of these processes would be essential. To
this end future studies should be performed in an unbiased
approach using a genome wide manner, and for this RNA
expression profiling seems promising since it has adequate
sensitivity due to the use of an PCR amplification step.
Therefore, by adapting the molecular approach to the
genome wide level, novel molecular blood markers forming
a ‘‘signature for AD’’ can hopefully be identified.
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